Abstract
Summary
Gilenya is an immunomodulating drug, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction.
The global market for Gilenya was estimated to be worth US$ 2013 million in 2023 and is forecast to a readjusted size of US$ 934.9 million by 2030 with a CAGR of -8.7% during the forecast period 2024-2030
The Gilenya market is primarily driven by the growing demand for effective treatments for multiple sclerosis (MS), particularly relapsing forms of the disease. Gilenya (fingolimod) is an oral medication that modulates immune system responses, aiming to reduce relapses and slow down disease progression. The increasing prevalence of MS and the need for therapies that offer convenience and improved quality of life contribute to market growth. Moreover, the shift from injectable to oral treatments and the potential to decrease relapse rates further propel adoption. However, challenges include potential cardiac effects during the initial dose and the need for monitoring patients for safety. Navigating the competitive landscape of MS treatments and addressing affordability and access barriers for a wider patient population are ongoing concerns. The market's success hinges on continuous research to enhance safety profiles, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and MS patient organizations to optimize MS management while addressing the evolving challenges associated with Gilenya therapy.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gilenya, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Gilenya by region & country, by Type, and by Application.
The Gilenya market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gilenya.
Market Segmentation
By Company
Novartis
Segment by Type:
28 Capsules/Box
96 Capsules/Box
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gilenya manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Gilenya in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Gilenya in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Gilenya was estimated to be worth US$ 2013 million in 2023 and is forecast to a readjusted size of US$ 934.9 million by 2030 with a CAGR of -8.7% during the forecast period 2024-2030
The Gilenya market is primarily driven by the growing demand for effective treatments for multiple sclerosis (MS), particularly relapsing forms of the disease. Gilenya (fingolimod) is an oral medication that modulates immune system responses, aiming to reduce relapses and slow down disease progression. The increasing prevalence of MS and the need for therapies that offer convenience and improved quality of life contribute to market growth. Moreover, the shift from injectable to oral treatments and the potential to decrease relapse rates further propel adoption. However, challenges include potential cardiac effects during the initial dose and the need for monitoring patients for safety. Navigating the competitive landscape of MS treatments and addressing affordability and access barriers for a wider patient population are ongoing concerns. The market's success hinges on continuous research to enhance safety profiles, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and MS patient organizations to optimize MS management while addressing the evolving challenges associated with Gilenya therapy.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gilenya, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Gilenya by region & country, by Type, and by Application.
The Gilenya market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gilenya.
Market Segmentation
By Company
Novartis
Segment by Type:
28 Capsules/Box
96 Capsules/Box
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gilenya manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Gilenya in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Gilenya in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Gilenya Product Introduction
1.2 Global Gilenya Market Size Forecast
1.2.1 Global Gilenya Sales Value (2019-2030)
1.2.2 Global Gilenya Sales Volume (2019-2030)
1.2.3 Global Gilenya Sales Price (2019-2030)
1.3 Gilenya Market Trends & Drivers
1.3.1 Gilenya Industry Trends
1.3.2 Gilenya Market Drivers & Opportunity
1.3.3 Gilenya Market Challenges
1.3.4 Gilenya Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gilenya Players Revenue Ranking (2023)
2.2 Global Gilenya Revenue by Company (2019-2024)
2.3 Global Gilenya Players Sales Volume Ranking (2023)
2.4 Global Gilenya Sales Volume by Company Players (2019-2024)
2.5 Global Gilenya Average Price by Company (2019-2024)
2.6 Key Manufacturers Gilenya Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Gilenya Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Gilenya
2.9 Gilenya Market Competitive Analysis
2.9.1 Gilenya Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Gilenya Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gilenya as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 28 Capsules/Box
3.1.2 96 Capsules/Box
3.2 Global Gilenya Sales Value by Type
3.2.1 Global Gilenya Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Gilenya Sales Value, by Type (2019-2030)
3.2.3 Global Gilenya Sales Value, by Type (%) (2019-2030)
3.3 Global Gilenya Sales Volume by Type
3.3.1 Global Gilenya Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Gilenya Sales Volume, by Type (2019-2030)
3.3.3 Global Gilenya Sales Volume, by Type (%) (2019-2030)
3.4 Global Gilenya Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Retail Pharmacy
4.1.2 Hospital Pharmacy
4.1.3 Other
4.2 Global Gilenya Sales Value by Application
4.2.1 Global Gilenya Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Gilenya Sales Value, by Application (2019-2030)
4.2.3 Global Gilenya Sales Value, by Application (%) (2019-2030)
4.3 Global Gilenya Sales Volume by Application
4.3.1 Global Gilenya Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Gilenya Sales Volume, by Application (2019-2030)
4.3.3 Global Gilenya Sales Volume, by Application (%) (2019-2030)
4.4 Global Gilenya Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Gilenya Sales Value by Region
5.1.1 Global Gilenya Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Gilenya Sales Value by Region (2019-2024)
5.1.3 Global Gilenya Sales Value by Region (2025-2030)
5.1.4 Global Gilenya Sales Value by Region (%), (2019-2030)
5.2 Global Gilenya Sales Volume by Region
5.2.1 Global Gilenya Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Gilenya Sales Volume by Region (2019-2024)
5.2.3 Global Gilenya Sales Volume by Region (2025-2030)
5.2.4 Global Gilenya Sales Volume by Region (%), (2019-2030)
5.3 Global Gilenya Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Gilenya Sales Value, 2019-2030
5.4.2 North America Gilenya Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Gilenya Sales Value, 2019-2030
5.5.2 Europe Gilenya Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Gilenya Sales Value, 2019-2030
5.6.2 Asia Pacific Gilenya Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Gilenya Sales Value, 2019-2030
5.7.2 South America Gilenya Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Gilenya Sales Value, 2019-2030
5.8.2 Middle East & Africa Gilenya Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gilenya Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Gilenya Sales Value
6.2.1 Key Countries/Regions Gilenya Sales Value, 2019-2030
6.2.2 Key Countries/Regions Gilenya Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Gilenya Sales Value, 2019-2030
6.3.2 United States Gilenya Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Gilenya Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Gilenya Sales Value, 2019-2030
6.4.2 Europe Gilenya Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Gilenya Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Gilenya Sales Value, 2019-2030
6.5.2 China Gilenya Sales Value by Type (%), 2023 VS 2030
6.5.3 China Gilenya Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Gilenya Sales Value, 2019-2030
6.6.2 Japan Gilenya Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Gilenya Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Gilenya Sales Value, 2019-2030
6.7.2 South Korea Gilenya Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Gilenya Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Gilenya Sales Value, 2019-2030
6.8.2 Southeast Asia Gilenya Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Gilenya Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Gilenya Sales Value, 2019-2030
6.9.2 India Gilenya Sales Value by Type (%), 2023 VS 2030
6.9.3 India Gilenya Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Company Information
7.1.2 Novartis Introduction and Business Overview
7.1.3 Novartis Gilenya Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Novartis Gilenya Product Offerings
7.1.5 Novartis Recent Development
8 Industry Chain Analysis
8.1 Gilenya Industrial Chain
8.2 Gilenya Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gilenya Sales Model
8.5.2 Sales Channel
8.5.3 Gilenya Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer